These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24142600)

  • 41. Long-acting insulin analogue detemir compared with NPH insulin in type 1 diabetes: a systematic review and meta-analysis.
    Szypowska A; Golicki D; Groele L; Pańkowska E
    Pol Arch Med Wewn; 2011; 121(7-8):237-46. PubMed ID: 21878861
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of switching from premixed insulin to insulin glargine regimen in Type 2 diabetes mellitus patients with different islet functions.
    Wang YB; Wang S; Bai R; Du JL; Xing Q; Ba Y; Yang Y; Zhang XY; Shi CH; Yao JJ
    Mol Med Rep; 2014 Aug; 10(2):1096-102. PubMed ID: 24859808
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The comparison of 24-hour urinary sodium, albumin, and protein excretion in chronic kidney disease patients with type 2 diabetes mellitus using insulin detemir or insulin glargine.
    Afsar B
    Clin Drug Investig; 2013 Oct; 33(10):773-8. PubMed ID: 23943142
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Higher dose requirements with insulin detemir in type 2 diabetes--three cases and a review of the literature.
    Swinnen SG; DeVries JH
    Diabetes Res Clin Pract; 2009 May; 84(2):e24-6. PubMed ID: 19251336
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treat-to-target trials: uses, interpretation and review of concepts.
    Garber AJ
    Diabetes Obes Metab; 2014 Mar; 16(3):193-205. PubMed ID: 23668598
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lower risk of hypoglycaemia and greater odds for weight loss with initiation of insulin detemir compared with insulin glargine in Turkish patients with type 2 diabetes mellitus: local results of a multinational observational study.
    Damci T; Emral R; Svendsen AL; Balkir T; Vora J;
    BMC Endocr Disord; 2014 Jul; 14():61. PubMed ID: 25048824
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Optimized glycaemic control achieved with add-on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized crossover trial comparing detemir versus glargine.
    Fadini GP; de Kreutzenberg SV; Mariano V; Boscaro E; Bertolini F; Mancuso P; Quarna J; Marescotti M; Agostini C; Tiengo A; Avogaro A
    Diabetes Obes Metab; 2011 Aug; 13(8):718-25. PubMed ID: 21410861
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differential effects of adiposity on pharmacodynamics of basal insulins NPH, glargine, and detemir in type 2 diabetes mellitus.
    Porcellati F; Lucidi P; Rossetti P; Candeloro P; Andreoli AM; Marzotti S; Cioli P; Bolli GB; Fanelli CG
    Diabetes Care; 2011 Dec; 34(12):2521-3. PubMed ID: 21972412
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
    Seufert J; Pegelow K; Bramlage P
    Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Distinct pharmacodynamics of insulin glargine and insulin detemir: crossover comparison in Type 1 and Type 2 diabetic patients on basal-bolus regimen.
    Kato T; Tokubuchi I; Muraishi K; Sato S; Kato T; Hara K; Tanaka K; Kaku H; Tajiri Y; Yamada K
    Diabetes Res Clin Pract; 2010 Dec; 90(3):e64-6. PubMed ID: 20850885
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Revisiting the efficacy of long-acting insulin analogues on adults with type 1 diabetes using mixed-treatment comparisons.
    Sanches AC; Correr CJ; Venson R; Pontarolo R
    Diabetes Res Clin Pract; 2011 Dec; 94(3):333-9. PubMed ID: 21992870
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Glycemic control and safety in Chinese patients with type 2 diabetes mellitus who switched from premixed insulin to insulin glargine plus oral antidiabetics: a large, prospective, observational study.
    Zhang B; Zhao J; Yang W;
    Diabetes Metab Res Rev; 2017 Mar; 33(3):. PubMed ID: 27667797
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Basal supplementation of insulin lispro protamine suspension versus insulin glargine and detemir for type 2 diabetes: meta-analysis of randomized controlled trials.
    Esposito K; Chiodini P; Capuano A; Petrizzo M; Improta MR; Giugliano D
    Diabetes Care; 2012 Dec; 35(12):2698-705. PubMed ID: 23173139
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents.
    Banerji MA; Baron MA; Gao L; Blonde L
    Postgrad Med; 2014 May; 126(3):111-25. PubMed ID: 24918797
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
    Lingvay I; Pérez Manghi F; García-Hernández P; Norwood P; Lehmann L; Tarp-Johansen MJ; Buse JB;
    JAMA; 2016 Mar; 315(9):898-907. PubMed ID: 26934259
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Differences between long-acting insulins for the treatment of type 2 diabetes.
    Jensen MG; Hansen M; Brock B; Rungby J
    Expert Opin Pharmacother; 2010 Aug; 11(12):2027-35. PubMed ID: 20642370
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
    Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog.
    Raslova K
    Vasc Health Risk Manag; 2010 Jun; 6():399-410. PubMed ID: 20539842
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapeutically interchangeable? A study of real-world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data.
    Levin P; Wei W; Miao R; Ye F; Xie L; Baser O; Gill J
    Diabetes Obes Metab; 2015 Mar; 17(3):245-53. PubMed ID: 25359227
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).
    Yki-Järvinen H; Bergenstal R; Ziemen M; Wardecki M; Muehlen-Bartmer I; Boelle E; Riddle MC;
    Diabetes Care; 2014 Dec; 37(12):3235-43. PubMed ID: 25193531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.